Long term risk of Herpes zoster in 1157 pts on tofacitinib for ulcerative colitis was Tofa 3.62 vs PBO 1.98/100PY during induction; during maintenace was Tofa 5mg 2.05 vs 10 mg 6.64 vs PBO 0.97/100PY. Higher risk w/ age, low wt, prior TNFi, N.American https://t.co/E3PGvejAUF https://t.co/k8PIT2o5KI

• https://bit.ly/3y2g8It

31 systemic JIA pts: w/ systemic sxs (n=8), chronic arthritis (7), remission on meds (10) & remission off meds (6). High IL-18 levels & impaired IL-18 signaling in NK cells correlated with systemic Dz activity. High IL-18 impairs NK phosphorylation https://t.co/hKTRdhuQVN https://t.co/qM5jYB3yi5

• https://bit.ly/3tK0VcL

Study of 1778 #SLE pts, of whom 121 had refractory thrombocytopenia (TP)(Plt <50K, unresp. to pred), Risk factors included pregnancy, Autoimmune hemolytic anemia, decreased C3, severity of TP and elevated ACL-IgG. https://t.co/ZNqQfUoYUq https://t.co/eQNcKcc9Uz

• https://bit.ly/39yllhQ

New podcast up, titled 'Two Week Twitter' Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.' https://t.co/tfBeKA0Arz https://t.co/CXYmEKNqDE

• https://bit.ly/3QyckGg

OA Initiative Study of 1212 knee OA pts (age 63 yrs), 73% walked for exercise. Walkers had signif. less New frequent knee pain (OR 0.6) & medial joint space narrowing (OR 0.8). Walking for exercise should be encouraged in knee OA pts. https://t.co/wCKjxwJ9EG

• https://bit.ly/3tOnBbF

Yesterday the FDA approved baricitinib (Olumiant) as the first systemic treatment for Alopecia Areata. Approval based on 2 DBRPCT Trial AA-1, AA-2) - 32% & 35% of pts on Bari 4 mg regrew scalp hair coverage by wk 36. https://t.co/QkB97B6Qjz https://t.co/5HmtBnpGqE

• https://bit.ly/39GP9sB

We've got a new download available titled "Travel Tips for Arthritis Travelers" Head over to RheumNow and download today. https://t.co/COamlQvlIs https://t.co/wxGBTtuv2f

• https://bit.ly/3QyPmi4

JAKi not yet safe in pregnancy - theyre fetotoxic at high doses (animals). JAKi do cross placenta. ACR Guidelines: no position due to no data. 47 tofa Rheum & 15 UC maternal exposures - no signif probs. Paternal use of JAKi is ok. https://t.co/PoIheshd2n https://t.co/gjTN2Uz4IP https://t.co/OAfLRvSFBs

• https://bit.ly/3tLzGhJ
• https://bit.ly/3O6J73s

#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj

• https://bit.ly/3xBn2D5

From OP Internationa: The Clinician’s Guide to prevention & Rx of OP -concise recommendations regarding prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women & men >50 yrs of age https://t.co/z3ZJ3lIplG

• https://bit.ly/3mXg6vl

Learn more about the IL-23 pathway and our clinical research in #psoriaticdisease here: https://t.co/jDuYR9fZ10 Sponsored by Janssen @JanssenUS@JanssenUS https://t.co/kjekl1teNX

• https://bit.ly/39yj0DC

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway? Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. https://t.co/QHNHsyWNbx https://t.co/Arlq03uiLE

• https://bit.ly/3OqeLZH

Flares Not Increased Following RZV Injections Insurance claims analysis has shown that the use of the RZV for prevention of HZ was highly used in patients with IMIDs and was safe, as higher rates of arthritis flares were not evident. https://t.co/E27oIBlEDb https://t.co/VbtDnmRYzO

• https://bit.ly/3NVvowp

Watch: Dr. Lucy Carter on RNA-Seq analysis to determine who's at risk for SLE Dr. Yusof interviews Dr. Lucy Carter ( @LucyCarter6), winner of the #EULAR2022 Best Abstract Award for her work on ANA positivity in those at-risk for progression to #SLE. https://t.co/BdPnZRgwX4 https://t.co/g8xWWFthVC

• https://bit.ly/3zFuobv